APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Medicine Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Nuclear Medicine Therapy Market Analysis and Forecast 2026-2032

2 January 2026196 pages

Choose your research edition.

Industry ResearchNuclear Medicine Therapy Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Medicine Therapy Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Nuclear Medicine Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Medicine Therapy Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Medicine Therapy Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Nuclear Medicine Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Nuclear Medicine Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Nuclear Medicine Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Nuclear Medicine Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Nuclear Medicine Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Nuclear Medicine Therapy include Aurobindo Pharma, China Isotope & Radiation, Curium Pharmaceuticals, International Isotopes, Jubilant Radiopharma, Lantheus, Mundipharma, Q BioMed and Bayer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Nuclear Medicine Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nuclear Medicine Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Nuclear Medicine Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nuclear Medicine Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nuclear Medicine Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nuclear Medicine Therapy revenue, projected growth trends, production technology, application and end-user industry.

Nuclear Medicine Therapy Segment by Company

Aurobindo Pharma

China Isotope & Radiation

Curium Pharmaceuticals

International Isotopes

Jubilant Radiopharma

Lantheus

Mundipharma

Q BioMed

Bayer

Dongcheng

Novartis

Nuclear Medicine Therapy Segment by Type

Lutetium-177

Radium-223

Iodine-131

Other

Nuclear Medicine Therapy Segment by Application

Bone Metastasis

Thyroid

Lymphoma

Other

Nuclear Medicine Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nuclear Medicine Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nuclear Medicine Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nuclear Medicine Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nuclear Medicine Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Lutetium-177 Major Player Table 3. Radium-223 Major Player Table 4. Iodine-131 Major Player Table 5. Other Major Player Table 6. Global Nuclear Medicine Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Bone Metastasis Major Player Table 8. Thyroid Major Player Table 9. Lymphoma Major Player Table 10. Other Major Player Table 11. Nuclear Medicine Therapy Industry Trends Table 12. Nuclear Medicine Therapy Industry Drivers Table 13. Nuclear Medicine Therapy Industry Opportunities and Challenges Table 14. Nuclear Medicine Therapy Industry Restraints Table 15. Global Nuclear Medicine Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Nuclear Medicine Therapy Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Nuclear Medicine Therapy Market Share by Region (2021-2026) Table 18. Global Nuclear Medicine Therapy Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Nuclear Medicine Therapy Market Share by Region (2027-2032) Table 20. Global Nuclear Medicine Therapy Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Nuclear Medicine Therapy Revenue Market Share by Players (2021-2026) Table 22. Global Nuclear Medicine Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Nuclear Medicine Therapy Key Players Headquarters & Area Served Table 24. Global Nuclear Medicine Therapy Players, Product Type & Application Table 25. Global Nuclear Medicine Therapy Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Nuclear Medicine Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Nuclear Medicine Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Nuclear Medicine Therapy Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Nuclear Medicine Therapy Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Nuclear Medicine Therapy Revenue Market Share by Type (2021-2026) Table 32. Global Nuclear Medicine Therapy Revenue Market Share by Type (2027-2032) Table 33. Global Nuclear Medicine Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Nuclear Medicine Therapy Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Nuclear Medicine Therapy Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Nuclear Medicine Therapy Revenue Market Share by Application (2021-2026) Table 37. Global Nuclear Medicine Therapy Revenue Market Share by Application (2027-2032) Table 38. Aurobindo Pharma Company Information Table 39. Aurobindo Pharma Business Overview Table 40. Aurobindo Pharma Nuclear Medicine Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Aurobindo Pharma Nuclear Medicine Therapy Product Portfolio Table 42. Aurobindo Pharma Recent Development Table 43. China Isotope & Radiation Company Information Table 44. China Isotope & Radiation Business Overview Table 45. China Isotope & Radiation Nuclear Medicine Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. China Isotope & Radiation Nuclear Medicine Therapy Product Portfolio Table 47. China Isotope & Radiation Recent Development Table 48. Curium Pharmaceuticals Company Information Table 49. Curium Pharmaceuticals Business Overview Table 50. Curium Pharmaceuticals Nuclear Medicine Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Curium Pharmaceuticals Nuclear Medicine Therapy Product Portfolio Table 52. Curium Pharmaceuticals Recent Development Table 53. International Isotopes Company Information Table 54. International Isotopes Business Overview Table 55. International Isotopes Nuclear Medicine Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. International Isotopes Nuclear Medicine Therapy Product Portfolio Table 57. International Isotopes Recent Development Table 58. Jubilant Radiopharma Company Information Table 59. Jubilant Radiopharma Business Overview Table 60. Jubilant Radiopharma Nuclear Medicine Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Jubilant Radiopharma Nuclear Medicine Therapy Product Portfolio Table 62. Jubilant Radiopharma Recent Development Table 63. Lantheus Company Information Table 64. Lantheus Business Overview Table 65. Lantheus Nuclear Medicine Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Lantheus Nuclear Medicine Therapy Product Portfolio Table 67. Lantheus Recent Development Table 68. Mundipharma Company Information Table 69. Mundipharma Business Overview Table 70. Mundipharma Nuclear Medicine Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Mundipharma Nuclear Medicine Therapy Product Portfolio Table 72. Mundipharma Recent Development Table 73. Q BioMed Company Information Table 74. Q BioMed Business Overview Table 75. Q BioMed Nuclear Medicine Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Q BioMed Nuclear Medicine Therapy Product Portfolio Table 77. Q BioMed Recent Development Table 78. Bayer Company Information Table 79. Bayer Business Overview Table 80. Bayer Nuclear Medicine Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Bayer Nuclear Medicine Therapy Product Portfolio Table 82. Bayer Recent Development Table 83. Dongcheng Company Information Table 84. Dongcheng Business Overview Table 85. Dongcheng Nuclear Medicine Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Dongcheng Nuclear Medicine Therapy Product Portfolio Table 87. Dongcheng Recent Development Table 88. Novartis Company Information Table 89. Novartis Business Overview Table 90. Novartis Nuclear Medicine Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Novartis Nuclear Medicine Therapy Product Portfolio Table 92. Novartis Recent Development Table 93. North America Nuclear Medicine Therapy Revenue by Type (2021-2026) & (US$ Million) Table 94. North America Nuclear Medicine Therapy Revenue by Type (2027-2032) & (US$ Million) Table 95. North America Nuclear Medicine Therapy Revenue by Application (2021-2026) & (US$ Million) Table 96. North America Nuclear Medicine Therapy Revenue by Application (2027-2032) & (US$ Million) Table 97. North America Nuclear Medicine Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. North America Nuclear Medicine Therapy Revenue by Country (2021-2026) & (US$ Million) Table 99. North America Nuclear Medicine Therapy Revenue by Country (US$ Million) & (2027-2032) Table 100. Europe Nuclear Medicine Therapy Revenue by Type (2021-2026) & (US$ Million) Table 101. Europe Nuclear Medicine Therapy Revenue by Type (2027-2032) & (US$ Million) Table 102. Europe Nuclear Medicine Therapy Revenue by Application (2021-2026) & (US$ Million) Table 103. Europe Nuclear Medicine Therapy Revenue by Application (2027-2032) & (US$ Million) Table 104. Europe Nuclear Medicine Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Europe Nuclear Medicine Therapy Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Nuclear Medicine Therapy Revenue by Country (US$ Million) & (2027-2032) Table 107. China Nuclear Medicine Therapy Revenue by Type (2021-2026) & (US$ Million) Table 108. China Nuclear Medicine Therapy Revenue by Type (2027-2032) & (US$ Million) Table 109. China Nuclear Medicine Therapy Revenue by Application (2021-2026) & (US$ Million) Table 110. China Nuclear Medicine Therapy Revenue by Application (2027-2032) & (US$ Million) Table 111. Asia Nuclear Medicine Therapy Revenue by Type (2021-2026) & (US$ Million) Table 112. Asia Nuclear Medicine Therapy Revenue by Type (2027-2032) & (US$ Million) Table 113. Asia Nuclear Medicine Therapy Revenue by Application (2021-2026) & (US$ Million) Table 114. Asia Nuclear Medicine Therapy Revenue by Application (2027-2032) & (US$ Million) Table 115. Asia Nuclear Medicine Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Asia Nuclear Medicine Therapy Revenue by Region (US$ Million) & (2021-2026) Table 117. Asia Nuclear Medicine Therapy Revenue by Region (US$ Million) & (2027-2032) Table 118. SAMEA Nuclear Medicine Therapy Revenue by Type (2021-2026) & (US$ Million) Table 119. SAMEA Nuclear Medicine Therapy Revenue by Type (2027-2032) & (US$ Million) Table 120. SAMEA Nuclear Medicine Therapy Revenue by Application (2021-2026) & (US$ Million) Table 121. SAMEA Nuclear Medicine Therapy Revenue by Application (2027-2032) & (US$ Million) Table 122. SAMEA Nuclear Medicine Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. SAMEA Nuclear Medicine Therapy Revenue by Country (2021-2026) & (US$ Million) Table 124. SAMEA Nuclear Medicine Therapy Revenue by Country (US$ Million) & (2027-2032) Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Nuclear Medicine Therapy Image Figure 2. Global Nuclear Medicine Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Medicine Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Lutetium-177 Image Figure 5. Radium-223 Image Figure 6. Iodine-131 Image Figure 7. Other Image Figure 8. Global Nuclear Medicine Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Nuclear Medicine Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 10. Bone Metastasis Image Figure 11. Thyroid Image Figure 12. Lymphoma Image Figure 13. Other Image Figure 14. Global Nuclear Medicine Therapy Market Size (US$ Million) & (2021-2032) Figure 15. Global Nuclear Medicine Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Nuclear Medicine Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Nuclear Medicine Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Nuclear Medicine Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Nuclear Medicine Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Nuclear Medicine Therapy Revenue Market Share by Type (2021-2032) Figure 22. Global Nuclear Medicine Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Nuclear Medicine Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Nuclear Medicine Therapy Revenue Market Share by Application (2021-2032) Figure 25. North America Nuclear Medicine Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Nuclear Medicine Therapy Revenue Share by Type (2021-2032) Figure 27. North America Nuclear Medicine Therapy Revenue Share by Application (2021-2032) Figure 28. North America Nuclear Medicine Therapy Revenue Share by Country (2021-2032) Figure 29. United States Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Nuclear Medicine Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Nuclear Medicine Therapy Revenue Share by Type (2021-2032) Figure 34. Europe Nuclear Medicine Therapy Revenue Share by Application (2021-2032) Figure 35. Europe Nuclear Medicine Therapy Revenue Share by Country (2021-2032) Figure 36. Germany Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Nuclear Medicine Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Nuclear Medicine Therapy Revenue Share by Type (2021-2032) Figure 46. China Nuclear Medicine Therapy Revenue Share by Application (2021-2032) Figure 47. Asia Nuclear Medicine Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Nuclear Medicine Therapy Revenue Share by Type (2021-2032) Figure 49. Asia Nuclear Medicine Therapy Revenue Share by Application (2021-2032) Figure 50. Asia Nuclear Medicine Therapy Revenue Share by Region (2021-2032) Figure 51. Japan Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Nuclear Medicine Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Nuclear Medicine Therapy Revenue Share by Type (2021-2032) Figure 59. SAMEA Nuclear Medicine Therapy Revenue Share by Application (2021-2032) Figure 60. SAMEA Nuclear Medicine Therapy Revenue Share by Country (2021-2032) Figure 61. Brazil Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Nuclear Medicine Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Lutetium-177
  • Radium-223
  • Iodine-131
  • Other
Applications
  • Bone Metastasis
  • Thyroid
  • Lymphoma
  • Other
Companies covered
  • Aurobindo Pharma
  • China Isotope & Radiation
  • Curium Pharmaceuticals
  • International Isotopes
  • Jubilant Radiopharma
  • Lantheus
  • Mundipharma
  • Q BioMed
  • Bayer
  • Dongcheng
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nuclear Medicine Therapy Market by Type
  3. 1.2.1 Global Nuclear Medicine Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Lutetium-177
  5. 1.2.3 Radium-223
  6. 1.2.4 Iodine-131
  7. 1.2.5 Other
  8. 1.3 Nuclear Medicine Therapy Market by Application
  9. 1.3.1 Global Nuclear Medicine Therapy Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Bone Metastasis
  11. 1.3.3 Thyroid
  12. 1.3.4 Lymphoma
  13. 1.3.5 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Nuclear Medicine Therapy Market Dynamics
  1. 2.1 Nuclear Medicine Therapy Industry Trends
  2. 2.2 Nuclear Medicine Therapy Industry Drivers
  3. 2.3 Nuclear Medicine Therapy Industry Opportunities and Challenges
  4. 2.4 Nuclear Medicine Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Nuclear Medicine Therapy Market Perspective (2021-2032)
  2. 3.2 Global Nuclear Medicine Therapy Growth Trends by Region
  3. 3.2.1 Global Nuclear Medicine Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nuclear Medicine Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Nuclear Medicine Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Nuclear Medicine Therapy Revenue by Players
  2. 4.1.1 Global Nuclear Medicine Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Nuclear Medicine Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Nuclear Medicine Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nuclear Medicine Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Nuclear Medicine Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Nuclear Medicine Therapy Players, Product Type & Application
  8. 4.5 Global Nuclear Medicine Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Nuclear Medicine Therapy Market CR5 and HHI
  11. 4.6.3 2025 Nuclear Medicine Therapy Tier 1, Tier 2, and Tier 3
5 Nuclear Medicine Therapy Market Size by Type
  1. 5.1 Global Nuclear Medicine Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Nuclear Medicine Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Nuclear Medicine Therapy Revenue Market Share by Type (2021-2032)
6 Nuclear Medicine Therapy Market Size by Application
  1. 6.1 Global Nuclear Medicine Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Nuclear Medicine Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Nuclear Medicine Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Aurobindo Pharma
  2. 7.1.1 Aurobindo Pharma Company Information
  3. 7.1.2 Aurobindo Pharma Business Overview
  4. 7.1.3 Aurobindo Pharma Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Aurobindo Pharma Nuclear Medicine Therapy Product Portfolio
  6. 7.1.5 Aurobindo Pharma Recent Developments
  7. 7.2 China Isotope & Radiation
  8. 7.2.1 China Isotope & Radiation Company Information
  9. 7.2.2 China Isotope & Radiation Business Overview
  10. 7.2.3 China Isotope & Radiation Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 China Isotope & Radiation Nuclear Medicine Therapy Product Portfolio
  12. 7.2.5 China Isotope & Radiation Recent Developments
  13. 7.3 Curium Pharmaceuticals
  14. 7.3.1 Curium Pharmaceuticals Company Information
  15. 7.3.2 Curium Pharmaceuticals Business Overview
  16. 7.3.3 Curium Pharmaceuticals Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Curium Pharmaceuticals Nuclear Medicine Therapy Product Portfolio
  18. 7.3.5 Curium Pharmaceuticals Recent Developments
  19. 7.4 International Isotopes
  20. 7.4.1 International Isotopes Company Information
  21. 7.4.2 International Isotopes Business Overview
  22. 7.4.3 International Isotopes Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 International Isotopes Nuclear Medicine Therapy Product Portfolio
  24. 7.4.5 International Isotopes Recent Developments
  25. 7.5 Jubilant Radiopharma
  26. 7.5.1 Jubilant Radiopharma Company Information
  27. 7.5.2 Jubilant Radiopharma Business Overview
  28. 7.5.3 Jubilant Radiopharma Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Jubilant Radiopharma Nuclear Medicine Therapy Product Portfolio
  30. 7.5.5 Jubilant Radiopharma Recent Developments
  31. 7.6 Lantheus
  32. 7.6.1 Lantheus Company Information
  33. 7.6.2 Lantheus Business Overview
  34. 7.6.3 Lantheus Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lantheus Nuclear Medicine Therapy Product Portfolio
  36. 7.6.5 Lantheus Recent Developments
  37. 7.7 Mundipharma
  38. 7.7.1 Mundipharma Company Information
  39. 7.7.2 Mundipharma Business Overview
  40. 7.7.3 Mundipharma Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Mundipharma Nuclear Medicine Therapy Product Portfolio
  42. 7.7.5 Mundipharma Recent Developments
  43. 7.8 Q BioMed
  44. 7.8.1 Q BioMed Company Information
  45. 7.8.2 Q BioMed Business Overview
  46. 7.8.3 Q BioMed Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Q BioMed Nuclear Medicine Therapy Product Portfolio
  48. 7.8.5 Q BioMed Recent Developments
  49. 7.9 Bayer
  50. 7.9.1 Bayer Company Information
  51. 7.9.2 Bayer Business Overview
  52. 7.9.3 Bayer Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bayer Nuclear Medicine Therapy Product Portfolio
  54. 7.9.5 Bayer Recent Developments
  55. 7.10 Dongcheng
  56. 7.10.1 Dongcheng Company Information
  57. 7.10.2 Dongcheng Business Overview
  58. 7.10.3 Dongcheng Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Dongcheng Nuclear Medicine Therapy Product Portfolio
  60. 7.10.5 Dongcheng Recent Developments
  61. 7.11 Novartis
  62. 7.11.1 Novartis Company Information
  63. 7.11.2 Novartis Business Overview
  64. 7.11.3 Novartis Nuclear Medicine Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Novartis Nuclear Medicine Therapy Product Portfolio
  66. 7.11.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Nuclear Medicine Therapy Revenue (2021-2032)
  2. 8.2 North America Nuclear Medicine Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Nuclear Medicine Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Nuclear Medicine Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Nuclear Medicine Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Nuclear Medicine Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Nuclear Medicine Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Nuclear Medicine Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Nuclear Medicine Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Nuclear Medicine Therapy Revenue by Country
  11. 8.6.1 North America Nuclear Medicine Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Nuclear Medicine Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Nuclear Medicine Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Nuclear Medicine Therapy Revenue (2021-2032)
  2. 9.2 Europe Nuclear Medicine Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Nuclear Medicine Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Nuclear Medicine Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Nuclear Medicine Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Nuclear Medicine Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Nuclear Medicine Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Nuclear Medicine Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Nuclear Medicine Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Nuclear Medicine Therapy Revenue by Country
  11. 9.6.1 Europe Nuclear Medicine Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Nuclear Medicine Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Nuclear Medicine Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Nuclear Medicine Therapy Revenue (2021-2032)
  2. 10.2 China Nuclear Medicine Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Nuclear Medicine Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Nuclear Medicine Therapy Revenue by Type (2027-2032)
  5. 10.3 China Nuclear Medicine Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Nuclear Medicine Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Nuclear Medicine Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Nuclear Medicine Therapy Revenue by Application (2027-2032)
  9. 10.5 China Nuclear Medicine Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nuclear Medicine Therapy Revenue (2021-2032)
  2. 11.2 Asia Nuclear Medicine Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Nuclear Medicine Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Nuclear Medicine Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Nuclear Medicine Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Nuclear Medicine Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Nuclear Medicine Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Nuclear Medicine Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Nuclear Medicine Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Nuclear Medicine Therapy Revenue by Country
  11. 11.6.1 Asia Nuclear Medicine Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Nuclear Medicine Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Nuclear Medicine Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nuclear Medicine Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Nuclear Medicine Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Nuclear Medicine Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Nuclear Medicine Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Nuclear Medicine Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Nuclear Medicine Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Nuclear Medicine Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Nuclear Medicine Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Nuclear Medicine Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Nuclear Medicine Therapy Revenue by Country
  11. 12.6.1 SAMEA Nuclear Medicine Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Nuclear Medicine Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Nuclear Medicine Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst